Recent Studies Show Cell-Based Vaccines Boost Flu Protection
Cell-Based Influenza Vaccines Show Enhanced Effectiveness
Recent observations from real-world evidence (RWE) data indicate a remarkable 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) when compared to standard egg-based quadrivalent vaccines (QIVe). This effectiveness is particularly noted in both pediatric and adult populations during the influenza season for ages six months to 64 years.
A Comprehensive Analysis of Vaccine Effectiveness
The study showcases consistent rVE across various demographics, including pediatric, adult, outpatient, and high-risk groups. With this being the fifth consecutive season of substantial retrospective test-negative studies, the superior protective nature of cell-based influenza vaccines reinforces their role in elevating the standard of care for influenza prevention.
The Study Framework
The collaborative effort between CSL Seqirus and a leading infectious disease epidemiologist involved a wide-ranging retrospective test-negative study. The research spanned individuals aged six months to 64 years who received influenza vaccines during the notable 2023/24 U.S. influenza season.
Key Findings from Vaccination Data
Data from 106,779 vaccinated individuals who underwent influenza testing revealed that cell-based vaccines provided better protection against confirmed influenza cases, illustrating a 19.8% rVE. This trend was observable across both age subgroups and those at heightened risk. Sensitivity analyses reinforced the robustness of these findings.
The Importance of Continuity in Vaccine Research
Dr. Gregg Sylvester, Chief Health Officer at CSL Seqirus, highlighted the relevance of these findings, especially after experiencing a significantly harsh influenza season previously. The statistics emphasize that behind every number lies a story, advocating for ongoing education regarding safe vaccinations, particularly for those six months and older.
Potential Impact on Healthcare
The research, using a compartmental influenza burden model, estimates that had all vaccinated individuals during the 2023/24 season received cell-based vaccines instead of standard egg-based ones, approximately 14,930 hospitalizations could have been avoided. Emphasizing the dynamic nature of the influenza virus, the study underscores the necessity of RWE studies to accurately determine vaccine efficacy each season.
Responding to Changes in Influenza
As Dr. Sheena Sullivan of Monash University pointed out, ongoing RWE studies highlight the greater efficacy of cell-based vaccines compared to their egg-based counterparts in preventing medically attended influenza cases. Adopting cell-based technology ensures a precise antigenic match to the vaccine strain selected by health authorities.
CSL Seqirus: A Leader in Vaccine Manufacturing
Located in Holly Springs, North Carolina, the CSL Seqirus facility stands as the world’s largest manufacturing plant for cell-based influenza vaccines. With capabilities in formulation and manufacturing of seasonal vaccines for international markets, CSL Seqirus plays a crucial role in global pandemic preparedness.
About CSL Seqirus
As a part of CSL (ASX: CSL), CSL Seqirus is among the largest providers of influenza vaccines worldwide. The company focuses on innovative vaccine technologies, including cell-based methods, to deliver a diverse range of vaccines recognized in over 20 countries.
Frequently Asked Questions
What is the benefit of cell-based influenza vaccines?
Cell-based vaccines have shown to be more effective than traditional egg-based vaccines, providing higher levels of immunity against influenza.
Who can receive cell-based influenza vaccines?
Individuals aged six months and older are eligible to receive these vaccines, as they provide better protection, especially for vulnerable populations.
How do cell-based vaccines compare in effectiveness?
Studies indicate that cell-based vaccines offer a 19.8% greater relative effectiveness in preventing confirmed cases of influenza.
What role does CSL Seqirus play in vaccine development?
CSL Seqirus is a leading provider of vaccines globally, focusing on innovative technology to enhance vaccine safety and effectiveness.
What should individuals consider before vaccination?
Individuals should consult with healthcare professionals to discuss their medical history, especially if they have a history of severe allergic reactions.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.